2023
DOI: 10.3390/biomedicines11082298
|View full text |Cite
|
Sign up to set email alerts
|

Preeclampsia and the Antiphospholipid Syndrome

Karoline Mayer-Pickel,
Manurishi Nanda,
Maja Gajic
et al.

Abstract: Antiphospholipid syndrome (APS) is characterized by venous or arterial thrombosis and/or adverse pregnancy outcome in the presence of persistent laboratory evidence of antiphospholipid antibodies (aPLs). Preeclampsia complicates about 10–17% of pregnancies with APS. However, only early onset preeclampsia (<34 weeks of gestation) belongs to the clinical criteria of APS. The similarities in the pathophysiology of early onset preeclampsia and APS emphasize an association of these two syndromes. Overall, both a… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
1
0
1

Year Published

2023
2023
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(2 citation statements)
references
References 196 publications
(264 reference statements)
0
1
0
1
Order By: Relevance
“…If there is an increased risk of uteroplacental dysfunction with the risk of IUGR, low-dose acetylsalicylic acid (ASA; 100–150 mg/die) should be started prophylactically at < 16 weeks gestation [ 102 ]. Patients with antiphospholipid syndrome (APS) should be advised before conception and treated with low-dose ASA and low-molecular-weight heparin from early pregnancy onwards [ 103 ]. Nutritional interventions supplementing the nitric oxide (NO) precursor levo-arginine had beneficial effects on fetoplacental circulation, birth weight, and neonatal outcomes [ 104 ].…”
Section: Strategies To Prevent or Mitigate Iugrmentioning
confidence: 99%
“…If there is an increased risk of uteroplacental dysfunction with the risk of IUGR, low-dose acetylsalicylic acid (ASA; 100–150 mg/die) should be started prophylactically at < 16 weeks gestation [ 102 ]. Patients with antiphospholipid syndrome (APS) should be advised before conception and treated with low-dose ASA and low-molecular-weight heparin from early pregnancy onwards [ 103 ]. Nutritional interventions supplementing the nitric oxide (NO) precursor levo-arginine had beneficial effects on fetoplacental circulation, birth weight, and neonatal outcomes [ 104 ].…”
Section: Strategies To Prevent or Mitigate Iugrmentioning
confidence: 99%
“…В большинстве случаев она возникает после 34 недель гестации. Раннее развитие (от 20 до 34 недель) и тяжёлое течение нефропатии беременных свойственно пациенткам с антифосфолипидным синдромом [35].…”
Section: факторы риска и течение преэклампсииunclassified